Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells

Experimental Cell Research

Volumn 318, Issue 13, 2012, Pages 1597-1610

  Hossain, Md Motarab ^a   Banik, Naren L ^b   Ray, Swapan K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

( ) Epigallocatechin 3 gallate; Angiogenesis; Apoptosis; Differentiation; Neuroblastoma; Survivin shRNA

Indexed keywords

ANTINEOPLASTIC AGENT; CALPAIN; CASPASE 3; CASPASE 8; CYTOCHROME C; EPIGALLOCATECHIN GALLATE; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF DIFFERENTIATION 2; NOTCH1 RECEPTOR; PROTEIN BID; PROTEIN KINASE B; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84862011023     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.03.033     Document Type: Article

References (40)

1. Hiyama E., Iehara T., Sugimoto T., Fukuzawa M., Hayashi Y., Sasaki F., Sugiyama M., Kondo S., Yoneda A., Yamaoka H., Tajiri T., Akazawa K., Ohtaki M. Effectiveness of screening for neuroblastoma at 6months of age: a retrospective population-based cohort study. Lancet 2008, 371:1173-1180.
2. Sampath J., Pelus L.M. Alternative splice variants of survivin as potential targets in cancer. Curr. Drug Discov. Technol. 2007, 4:174-191.
3. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 2006, 18:609-615.
4. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
5. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244:164-171.
6. Yamamoto H., Ngan C.Y., Monden M. Cancer cells survive with survivin. Cancer Sci. 2008, 99:1709-1714.
7. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277:3247-3257.
8. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 2008, 12:463-476.
9. Das A., Banik N.L., Ray S.K. Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. Int. J. Cancer 2006, 119:2575-2585.
10. Chen C., Shen G., Hebbar V., Hu R., Owuor E.D., Kong A.N. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 2003, 24:1369-1378.
11. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27:2055-2063.
12. Mittal A., Pate M.S., Wylie R.C. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int. J. Oncol. 2004, 24:703-710.
13. Shankar S., Ganapathy S., Hingorani S.R., Srivastava R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front. Biosci. 2008, 13:440-445.
14. Rasper M., Schafer A., Piontek G., Teufel J., Brockhoff G., Ringel F., Heindl S., Zimmer C., Schlegel J. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncol. 2010, 12:1024-1033.
15. Mohan N., Karmakar S., Banik N.L., Ray S.K. SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. Neurochem. Res. 2011, 36:1383-1396.
16. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
17. Jung Y.D., Kim M.S., Shin B.A., Chay K.O., Ahn B.W., Liu W., Bucana C.D., Gallick G.E., Ellis L.M. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer 2001, 84:844-850.
18. Brierley-Hobson S. Binding of (-)-epigallocatechin-3-gallate to the Hsp70 ATPase domain may promote apoptosis in colorectal cancer. Biosci. Horiz. 2001, 1:9-18.
19. Qanungo S., Das M., Haldar S., Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26:958-967.
20. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., Ohira M., Hashizume K., Kobayashi H., Kaneko Y., Nakagawara A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
21. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., Patnaik A., Papadopoulos K., Takimoto C., Bartels P., Keating A., Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of surviving. J. Clin. Oncol. 2008, 26:5198-5203.
22. Mohan N., Banik N.L., Ray S.K. Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis. Cancer Biol. Ther. 2011, 12:846-854.
23. Jögi A., Øra I., Nilsson H., Lindeheim H., Makino Y., Poellinger L., Axelson H., Påhlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7021-7026.
24. Kim S., Schein A.J., Nadel J.A. E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L1049-L1060.
25. Janardhanan R., Banik N.L., Ray S.K. N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Biochem. Pharmacol. 2009, 78:1105-1214.
26. Chandele A., Prasad V., Jagtap J.C., Shukla R., Shastry P.R. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 2004, 6:29-40.
27. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., Chung C.W., Jung Y.K., Oh B.H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
28. Roy M., Chakrabarty S., Sinha D., Bhattacharya R.K., Siddiqi M. Anti-clastogenic, anti-genotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutat. Res. 2003, 523-524:33-41.
29. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
30. Song Z., Yao X., Wu M. Direct interaction between survivin and smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem. 2003, 278:23130-23140.
31. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
32. Choudhury S.R., Karmakar S., Banik N.L., Ray S.K. Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells. Neurochem. Res. 2011, 26:2292-2305.
33. Karmakar S., Banik N.L., Patel S.J., Ray S.K. Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci. Lett. 2006, 407:53-58.
34. George J., Banik N.L., Ray S.K. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem. Res. 2009, 34:66-78.
35. Karmakar S., Choudhury S.R., Banik N.L., Ray S.K. Activation of multiple molecular mechanisms for increasing apoptosis in human glioblastoma T98G xenograft. J. Cancer Sci. Ther. 2010, 2:107-113.
36. Sun X.M., MacFarlane M., Zhuang J., Wolf B.B., Green D.R., Cohen G.M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 1999, 274:5053-5060.
37. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., Eshraghi M., Manda K.D., Wiechec E., Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 2007, 10:13-29.
38. Pelloski C.E., Lin E., Zhang L., Yung W.K., Colman H., Liu J.L., Woo S.Y., Heimberger A.B., Suki D., Prados M., Chang S., Barker F.G., Fuller G.N., Aldape K.D. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin. Cancer Res. 2006, 12:3935-3941.
39. Argyriou A.A., Giannopoulou E., Kalofonos H.P. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 2009, 77:1-11.
40. Plate K.H., Breier G., Weich H.A., Mennel H.D., Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer 1994, 59:520-529.